Amphastar Pharmaceuticals Inc

Insider selling at Amphastar shows routine liquidity moves, not distress, while a $50M share‑repurchase boost supports stock value and investor confidence.

Amphastar’s CFO insider sale is a routine tax‑settlement, not a sign of distress – the company’s resilient injectable pipeline and share‑repurchase program keep its growth prospects strong.

Amphastar CFO William J. Peters buys 58,693 shares, signalling bullish confidence as the stock struggles; investors track his RSU and option activity for potential upside.

Amphastar insider buy: Zhou Rong’s 39k‑share purchase amid volatility signals confidence in the company’s drug pipeline and long‑term value.

Amphastar’s insider RSU purchase, LipaCure‑101 phase IIb results, and breakthrough‑therapy filing signal strong growth potential for oncology and metabolic therapies.

Amphastar’s CEO buys RSUs, signaling confidence despite market drops—explore how niche generics, accelerated approvals, and risk‑sharing deals shape its growth strategy.

Jack Zhang’s March 2026 sale of 5,769 Amphastar shares suggests routine RSU tax‑planning, not a confidence warning—investors should monitor pipeline milestones and insider trends for clearer signals.

Amphastar insider sales reveal routine tax‑planning, not a shift in confidence, amid tech upgrades and reimbursement changes that shape its future value.